Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.58 |
| ▸ | RRM1 | P23921 | 1/20 | 0.58 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 3/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11035085 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL10248180 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL18896155 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL25454649 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL16410230 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL24072564 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL19910579 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL14076747 | 1.00 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1CASP2 | |
| SCHEMBL1753873 | 0.98 | DPP7 (0.60) | EPHX1MMP8DPP7RRM1CASP2 | |
| Bromide SCHEMBL29127625 | 0.96 | EPHX1 (0.57) | EPHX1MMP8DPP7RRM1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-117616094-A | Adhesive tape laminate, microfluidic chip, and microfluidic device | 积水化学工业株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023091985-A1 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | DTX PHARMA, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-116004005-A | Cyclic imide resin composition, liquid adhesive, film, prepreg, copper-clad laminate, and printed wiring board | 信越化学工业株式会社 | 2023-04-25 | — | — | CN | disclosed |
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022092150-A1 | MICROFLUIDIC CHIP, CELL ANALYSIS DEVICE, CELL ANALYSIS SYSTEM, AND CELL ANALYSIS METHOD | 積水化学工業株式会社 | 2022-05-05 | — | — | WO | disclosed |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | WASHINGTON UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2021108640-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DTX PHARMA, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021055376-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| CN-1585809-A | Adhesive material, method for peeling adhesive material, and adhesive tape | SEKISUI CHEMICAL CO LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| CN-1537151-A | Pressure sensitive adhesive double coated tape and method for producing IC chip using it | ��Ԩ��ѧ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| EP-0792869-B1 | Azoamide compounds and their use as polymerization initiators | WAKO PURE CHEM IND LTD (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-5849888-A | Azoamide compound | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0792869-A1 | Azoamide compounds and their use as polymerization initiators | WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) | 1997-09-03 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | EPHX1 3578/4885MMP8 2165/4885DPP7 972/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | EPHX1 4672/4885MMP8 2074/4885DPP7 766/4885 |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | HDGF, MMP7, HGF | EPHX1 1177/4885MMP8 73/4885DPP7 354/4885 |
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | EPHX1 1177/4885MMP8 73/4885DPP7 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.